Cerebrospinal fluid biomarkers for Dementia with Lewy Bodies

International Journal of Alzheimer's Disease

Volumn , Issue , 2010, Pages

  Mukaetova Ladinska, Elizabeta B ^a   Monteith, Rachael ^a   Perry, Elaine K ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PROTEIN; BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; CALCIUM; COCAINE AND AMPHETAMINE REGULATED TRANSCRIPT PEPTIDE; COPPER; DOPAMINE; GAMMA SYNUCLEIN; IMMUNOGLOBULIN G; MAGNESIUM; NEUROTRANSMITTER; NITRIC OXIDE; OREXIN A; PREALBUMIN; TAU PROTEIN;

CEREBROSPINAL FLUID ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; DEMENTIA; DOT HYBRIDIZATION; ELECTROENCEPHALOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; HOMEOSTASIS; HUMAN; LEWY BODY; LONG TERM CARE; MYOCARDIAL PERFUSION IMAGING; NEUROIMAGING; NEUROPATHOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN PROCESSING; RADIOIMMUNOASSAY; RECEIVER OPERATING CHARACTERISTIC; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; WESTERN BLOTTING;

EID: 78349256701     PISSN: None     EISSN: 20900252     Source Type: Journal    
DOI: 10.4061/2010/536538     Document Type: Review

References (125)

1. Knapp M., Prince M., Albanese E., A report into the prevalence and cost of dementia Alzheimers society. London, UK, 2007
2. Barber R., Panikkar A., McKeith I. G., Dementia with Lewy bodies: diagnosis and management International Journal of Geriatric Psychiatry 2001 16 1 S12 S18
3. McKeith I. G., Galasko D., Kosaka K., Perry E. K., Dickson D. W., Hansen L. A., Salmon D. P., Lowe J., Mirra S. S., Byrne E. J., Lennox G., Quinn N. P., Edwardson J. A., Ince P. G., Bergeron C., Burns A., Miller B. L., Lovestone S., Collerton D., Jansen E. N. H., Ballard C., De Vos R. A. I., Wilcock G. K., Jellinger K. A., Perry R. H., Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop Neurology 1996 47 5 1113 1124
4. McKeith I., Mintzer J., Aarsland D., International psychogeriatric association expert meeting on DLB (Dementia with Lewy bodies) Lancet Neurology 2004 3 19 28
5. McKeith I. G., Dickson D. W., Lowe J., Emre M., O'Brien J. T., Feldman H., Cummings J., Duda J. E., Lippa C., Perry E. K., Aarsland D., Arai H., Ballard C. G., Boeve B., Burn D. J., Costa D., Del Ser T., Dubois B., Galasko D., Gauthier S., Goetz C. G., Gomez-Tortosa E., Halliday G., Hansen L. A., Hardy J., Iwatsubo T., Kalaria R. N., Kaufer D., Kenny R. A., Korczyn A., Kosaka K., Lee V. M. Y., Lees A., Litvan I., Londos E., Lopez O. L., Minoshima S., Mizuno Y., Molina J. A., Mukaetova-Ladinska E. B., Pasquier F., Perry R. H., Schulz J. B., Trojanowski J. Q., Yamada M., Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium Neurology 2005 65 12 1863 1872
6. Verghese J., Crystal H. A., Dickson D. W., Lipton R. B., Validity of clinical criteria for the diagnosis of dementia with Lewy bodies Neurology 1999 53 9 1974 1982
7. McKeith I. G., Ballard C. G., Perry R. H., Ince P. G., O'Brien J. T., Neill D., Lowery K., Jaros E., Barber R., Thompson P., Swann A., Fairbairn A. F., Perry E. K., Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies Neurology 2000 54 5 1050 1058
8. Tiraboschi P., Salmon D. P., Hansen L. A., Hofstetter R. C., Thal L. J., Corey-Bloom J., What best differentiates Lewy body from Alzheimer's disease in early-stage dementia? Brain 2006 129 3 729 735
9. Jellinger K. A., In dementia with Lewy bodies, Braak stage determines phenotype, not Lewy body distribution Neurology 2008 70 5 407 408
10. Noe E., Marder K., Bell K. L., Jacobs D. M., Manly J. J., Stern Y., Comparison of dementia with Lewy bodies to Alzheimer's disease and Parkinson's disease with dementia Movement Disorders 2004 19 1 60 67
11. Bosboom J. L. W., Wolters E., Psychotic symptoms in Parkinson's disease: pathophysiology and management Expert Opinion on Drug Safety 2004 3 3 209 220
12. Burton E. J., Barber R., Mukaetova-Ladinska E. B., Robson J., Perry R. H., Jaros E., Kalaria R. N., O'Brien J. T., Medial temporal lobe atrophy on MRI differentiates Alzheimer's disease from dementia with Lewy bodies and vascular cognitive impairment: a prospective study with pathological verification of diagnosis Brain 2009 132 1 195 203
13. Lobotesis K., Fenwick J. D., Phipps A., Ryman A., Swann A., Ballard C., McKeith I. G., O'Brien J. T., Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD Neurology 2001 56 5 643 649 (Pubitemid 32209999)
14. Shimizu S., Hanyu H., Kanetaka H., Iwamoto T., Koizumi K., Abe K., Differentiation of dementia with Lewy bodies from Alzheimer's disease using brain SPECT Dementia and Geriatric Cognitive Disorders 2005 20 1 25 30
15. Kemp P. M., Hoffmann S. A., Tossici-Bolt L., Fleming J. S., Holmes C., Limitations of the HMPAO SPECT appearances of occipital lobe perfusion in the differential diagnosis of dementia with Lewy bodies Nuclear Medicine Communications 2007 28 6 451 456
16. Kgi G., Bhatia K. P., Tolosa E., The role of DAT-SPECT in movement disorders Journal of Neurology Neurosurgery and Psychiatry 2010 81 5 12
17. Edison P., Archer H. A., Hinz R., Hammers A., Pavese N., Tai Y. F., Hotton G., Cutler D., Fox N., Kennedy A., Rossor M., Brooks D. J., Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study Neurology 2007 68 7 501 508
18. Maetzler W., Liepelt I., Reimold M., Reischl G., Solbach C., Becker C., Schulte C., Leyhe T., Keller S., Melms A., Gasser T., Berg D., Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics Neurobiology of Disease 2009 34 1 107 112
19. Taki J., Yoshita M., Yamada M., Tonami N., Significance of 123I-MIBG scintigraphy as a pathophysiological indicator in the assessment of Parkinson's disease and related disorders: It can be a specific marker for Lewy body disease Annals of Nuclear Medicine 2004 18 6 453 461
20. Yoshita M., Taki J., Yokoyama K., Noguchi-Shinohara M., Matsumoto Y., Nakajima K., Yamada M., Value of I123 -MIBG radioactivity in the differential diagnosis of DLB from AD Neurology 2006 66 12 1850 1854
21. Schmidt S. L., Correa P. L., Tolentino J. C., Manhes A. C., Felix R. M., Azevedo J. C., Barbirato G. B., Mendes M. H. F., Boechat Y., Cabral H., Schmidt G. J., Dohmann H. F., Mesquita C. T., Value of combining activated brain FDG-PET and cardiac MIBG for the differential diagnosis of dementia: differentiation of dementia with Lewy bodies and Alzheimer disease when the diagnoses based on clinical and neuroimaging criteria are difficult Clinical Nuclear Medicine 2008 33 6 398 401
22. Novellino F., Bagnato A., Salsone M., Cascini G. L., Nicoletti G., Arabia G., Pugliese P., Morelli M., Paglionico S., Cipullo S., Manna I., De Marco E. V., Condino F., Chiriaco C., Morgante L., Zappia M., Quattrone A., Myocardial 123I-MIBG scintigraphy for differentiation of Lewy bodies disease from FTD Neurobiology of Aging 2010 31 11 1903 1911
23. Jacobson A. F., Senior R., Cerqueira M. D., Wong N. D., Thomas G. S., Lopez V. A., Agostini D., Weiland F., Chandna H., Narula J., Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure: results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study Journal of the American College of Cardiology 2010 55 20 2212 2221
24. Ueshima H., Sekikawa A., Miura K., Turin T. C., Takashima N., Kita Y., Watanabe M., Kadota A., Okuda N., Kadowaki T., Nakamura Y., Okamura T., Cardiovascular disease and risk factors in Asia: a selected review Circulation 2008 118 25 2702 2709
25. Xuereb J. H., Brayne C., Dufouil C., Gertz H., Wischik C., Harrington C., Mukaetova-Ladinska E., McGee M. A., O'Sullivan A., O'Connor D., Paykel E. S., Huppert F. A., Neuropathological findings in the very old. Results from the first 101 brains of a population-based longitudinal study of dementing disorders Annals of the New York Academy of Sciences 2000 903 490 496
26. Matthews F. E., Jagger C., Miller L. L., Brayne C., Education differences in life expectancy with cognitive impairment Journals of Gerontology A 2009 64 1 125 131
27. Ballard C. G., Jacoby R., Del Ser T., Khan M. N., Munoz D. G., Holmes C., Nagy Z., Perry E. K., Joachim C., Jaros E., O'Brien J. T., Perry R. H., McKeith I. G., Neuropathological substrates of psychiatric symptoms in prospectively studied patients with autopsy-confirmed dementia with Lewy bodies American Journal of Psychiatry 2004 161 5 843 849
28. Hamilton J. M., Salmon D. P., Galasko D., Raman R., Emond J., Hansen L. A., Masliah E., Thal L. J., Visuospatial deficits predict rate of cognitive decline in autopsy verified dementia with Lewy bodies Neuropsychology 2008 22 6 729 737
29. Samuel W., Alford M., Hofstetter C. R., Hansen L., Dementia with Lewy bodies versus pure Alzheimer disease: differences in cognition, neuropathology, cholinergic dysfunction, and synapse density Journal of Neuropathology and Experimental Neurology 1997 56 5 499 508
30. Hamilton R. L., Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using α-synuclein immunohistochemistry Brain Pathology 2000 10 3 378 384
31. Lopez O. L., Becker J. T., Sweet R. A., Martin-Sanchez F. J., Hamilton R. L., Lewy bodies in the amygdala increase risk for major depression in subjects with Alzheimer disease Neurology 2006 67 4 660 665
32. Olichney J. M., Galasko D., Salmon D. P., Hofstetter C. R., Hansen L. A., Katzman R., Thal L. J., Cognitive decline is faster in Lewy body variant than in Alzheimer's disease Neurology 1998 51 2 351 357 (Pubitemid 28406305)
33. Baker M., In biomarkers we trust? Nature Biotechnology 2005 23 3 297 304
34. Shapiro D. E., The interpretation of diagnostic tests Statistical Methods in Medical Research 1999 8 2 113 134
35. Davidsson P., Paulson L., Hesse C., Blennow K., Nilsson C. L., Proteome studies of human cerebrospinal fluid and brain tissue using a preparative two-dimensional electophoresis approach prior to mass spectrometry Proteomics 2001 1 3 444 452
36. Mukaetova-Ladinska E. B., McKeith I. G., Pathophysiology of synuclein aggregation in Lewy body disease Mechanisms of Ageing and Development 2006 127 2 188 202
37. Raghavan R., Kruijff L., Sterrenburg M. D., Rogers B. B., Hladik C. L., White C. L. III, Alphaα-synuclein expression in the developing human brain Pediatric and Developmental Pathology 2004 7 5 506 516
38. Fujiwara H., Hasegawa M., Dohmae N., Kawashima A., Masliah E., Goldberg M. S., Shen J., Takio K., Iwatsubo T., α-synuclein is phosphorylated in synucleinopathy lesions Nature Cell Biology 2002 4 2 160 164
39. Obi K., Akiyama H., Kondo H., Shimomura Y., Hasegawa M., Iwatsubo T., Mizuno Y., Mochizuki H., Relationship of phosphorylated α-synuclein and tau accumulation to A deposition in the cerebral cortex of dementia with Lewy bodies Experimental Neurology 2008 210 2 409 420
40. Tsuang D. W., DiGiacomo L., Bird T. D., Familial occurrence of dementia with Lewy bodies American Journal of Geriatric Psychiatry 2004 12 2 179 188
41. Singleton A. B., Farrer M., Johnson J., Singleton A., Hague S., Kachergus J., Hulihan M., Peuralinna T., Dutra A., Nussbaum R., Lincoln S., Crawley A., Hanson M., Maraganore D., Adler C., Cookson M. R., Muenter M., Baptista M., Miller D., Blancato J., Hardy J., Gwinn-Hardy K., α-synuclein locus triplication causes Parkinson's disease Science 2003 302 5646 841
42. Borghi R., Marchese R., Negro A., Marinelli L., Forloni G., Zaccheo D., Abbruzzese G., Tabaton M., Full length α-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects Neuroscience Letters 2000 287 1 65 67
43. El-Agnaf O. M. A., Irvine G. B., Aggregation and neurotoxicity of α-synuclein and related peptides Biochemical Society Transactions 2002 30 4 559 565
44. Ballard C., Jones E. L., Londos E., Minthon L., Francis P., Aarsland D., α-synuclein antibodies recognize a protein present at lower levels in the CSF of patients with dementia with Lewy bodies International Psychogeriatrics 2010 22 321 327
45. Mukaetova-Ladinska E. B., Milne J., Andras A., Abdel-All Z., Cerejeira J., Greally E., Robson J., Jaros E., Perry R., McKeith I. G., Brayne C., Xuereb J., Cleghorn A., Doherty J., McIntosh G., Milton I., Alpha- and gammaα-synuclein proteins are present in cerebrospinal fluid and are increased in aged subjects with neurodegenerative and vascular changes Dementia and Geriatric Cognitive Disorders 2008 26 1 32 42
46. Noguchi-Shinohara M., Tokuda T., Yoshita M., Kasai T., Ono K., Nakagawa M., El-Agnaf O. M. A., Yamada M., CSF α-synuclein levels in dementia with Lewy bodies and Alzheimer's disease Brain Research 2009 1251 1 6
47. Gmez-Tortosa E., Newell K., Irizarry M. C., Albert M., Growdon J. H., Hyman B. T., Clinical and quantitative pathologic correlates of dementia with Lewy bodies Neurology 1999 53 6 1284 1291
48. Spies P. E., Melis R. J. F., Sjgren M. J. C., Rikkert M. G. M. O., Verbeek M. M., Cerebrospinal fluid α-synuclein does not discriminate between dementia disorders Journal of Alzheimer's Disease 2009 16 2 363 369
49. hrfelt A., Grognet P., Andreasen N., Wallin A., Vanmechelen E., Blennow K., Zetterberg H., Cerebrospinal fluid α-synuclein in neurodegenerative disorders-A marker of synapse loss? Neuroscience Letters 2009 450 3 332 335
50. Mukaetova-Ladinska E.B., Garcia-Siera F., Hurt J., Gertz H. J., Xuereb J. H., Hills R., Brayne C., Huppert F. A., Paykel E. S., McGee M., Jakes R., Honer W. G., Harrington C. R., Wischik C. M., Staging of cytoskeletal and -amyloid changes in human isocortex reveals biphasic synaptic protein response during progression of Alzheimer's disease American Journal of Pathology 2000 157 2 623 636
51. Mollenhauer B., Cullen V., Kahn I., Krastins B., Outeiro T. F., Pepivani I., Ng J., Schulz-Schaeffer W., Kretzschmar H. A., McLean P. J., Trenkwalder C., Sarracino D. A., VonSattel J.-P., Locascio J. J., El-Agnaf O. M. A., Schlossmacher M. G., Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration Experimental Neurology 2008 213 2 315 325
52. Kasuga K., Tokutake T., Ishikawa A., Uchiyama T., Tokuda T., Onodera O., Nishizawa M., Ikeuchi T., Differential levels of α-synuclein, -amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease Journal of Neurology, Neurosurgery and Psychiatry 2010 81 6 608 610
53. Sironi F., Trotta L., Antonini A., Zini M., Ciccone R., Della Mina E., Meucci N., Sacilotto G., Primignani P., Brambilla T., Coviello D. A., Pezzoli G., Goldwurm S., α-synuclein multiplication analysis in Italian familial Parkinson disease Parkinsonism and Related Disorders 2010 16 3 228 231
54. Arai H., Terajima M., Miura M., Higuchi S., Muramatsu T., Machida N., Seiki H., Takase S., Clark C. M., Lee V. M.-Y., Trojanowski J. Q., Sasaki H., Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease Annals of Neurology 1995 38 4 649 652
55. Parnetti L., Lanari A., Amici S., Gallai V., Vanmechelen E., Hulstaert F., CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies Neurological Sciences 2001 22 1 77 78
56. Clark C. M., Xie S., Chittams J., Ewbank D., Peskind E., Galasko D., Morris J. C., McKeel D. W. Jr., Farlow M., Weitlauf S. L., Quinn J., Kaye J., Knopman D., Arai H., Doody R. S., DeCarli C., Leight S., Lee V. M.-Y., Trojanowski J. Q., Cerebrospinal fluid tau and -amyloid Archives of Neurology 2003 60 12 1696 1702
57. Hampel H., Buerger K., Zinkowski R., Teipel S. J., Goernitz A., Andreasen N., Sjoegren M., DeBernardis J., Kerkman D., Ishiguro K., Ohno H., Vanmechelen E., Vanderstichele H., McCulloch C., Mller H.-J., Davies P., Blennow K., Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study Archives of General Psychiatry 2004 61 1 95 102
58. Parnetti L., Tiraboschi P., Lanari A., Peducci M., Padiglioni C., D'Amore C., Pierguidi L., Tambasco N., Rossi A., Calabresi P., Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies Biological Psychiatry 2008 64 10 850 855
59. Vanderstichele H., De Vreese K., Blennow K., Andreasen N., Sindic C., Ivanoiu A., Hampel H., Brger K., Parnetti L., Lanari A., Padovani A., DiLuca M., Blser M., Ohrfelt Olsson A., Pottel H., Hulstaert F., Vanmechelen E., Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU(181P) assay for discrimination between Alzheimer's disease and dementia with Lewy bodies Clinical Chemistry and Laboratory Medicine 2006 44 12 1472 1480
60. Simic G., Boban M., Sarac H., CSF tau proteins in evaluation of patients with suspected dementia New Trends in Alzheimer and Parkinson Related Disorders, ADPD 2007 2007 Salzburg, Austria Medimond
61. Koopman K., Le Bastard N., Martin J.-J., Nagels G., De Deyn P. P., Engelborghs S., Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau181P Neurochemistry International 2009 55 4 214 218
62. Mattsson N., Zetterberg H., Hansson O., Andreasen N., Parnetti L., Jonsson M., Herukka S. K., CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment JAMA 2009 302 4 385 393
63. Spies P. E., Sjgren J. M., Kremer B. P., Verhey F. R., Rikkert M. G., Verbeek M. M., The cerebrospinal fluid amyloid beta (42/40) ratio in the differentiation of Alzheimers disease from non-Alzheimers dementia Current Alzheimer Research 2010 7 5 470 476
64. Bibl M., Mollenhauer B., Esselmann H., Lewczuk P., Klafki H.-W., Sparbier K., Smirnov A., Cepek L., Trenkwalder C., Rther E., Kornhuber J., Otto M., Wiltfang J., CSF amyloid- -peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia Brain 2006 129 5 1177 1187
65. Bibl M., Mollenhauer B., Esselmann H., Lewczuk P., Trenkwalder C., Brechlin P., Rther E., Kornhuber J., Otto M., Wiltfang J., CSF diagnosis of Alzheimer's disease and dementia with Lewy bodies Journal of Neural Transmission 2006 113 11 1771 1778
66. Wada-Isoe K., Michio K., Imamura K., Nakaso K., Kusumi M., Kowa H., Nakashima K., Serum proteomic profiling of dementia with Lewy bodies: diagnostic potential of SELDI-TOF MS analysis Journal of Neural Transmission 2007 114 12 1579 1583
67. Wada-Isoe K., Kitayama M., Nakaso K., Nakashima K., Diagnostic markers for diagnosing dementia with Lewy bodies: CSF and MIBG cardiac scintigraphy study Journal of the Neurological Sciences 2007 260 1-2 33 37
68. Bostrm F., Hansson O., Gerhardsson L., Lundh T., Minthon L., Stomrud E., Zetterberg H., Londos E., CSF Mg and Ca as diagnostic markers for dementia with Lewy bodies Neurobiology of Aging 2009 30 8 1265 1271
69. Molina J. A., Leza J. C., Ortiz S., Moro M. A., Prez S., Lizasoan I., Urigen L., Oliva J. M., Manzanares J., Cerebrospinal fluid and plasma concentrations of nitric oxide metabolites are increased in dementia with Lewy bodies Neuroscience Letters 2002 333 2 151 153
70. Molina J. A., Gmez P., Vargas C., Ortiz S., Prez-Rial S., Urigen L., Oliva J. M., Villanueva C., Manzanares J., Neurotransmitter amino acid in cerebrospinal fluid of patients with dementia with Lewy bodies Journal of Neural Transmission 2005 112 4 557 563
71. Schultz K., Wiehager S., Nilsson K., Nielsen J. E., Lindquist S. G., Hjermind L. E., Andersen B. B., Wallin A., Nilsson C., Petersn A., Reduced CSF CART in dementia with Lewy bodies Neuroscience Letters 2009 453 2 104 106
72. Schultz K., Nilsson K., Nielsen J. E., Lindquist S. G., Hjermind L. E., Andersen B. B., Wallin A., Nilsson C., Petersn., Transthyretin as a potential CSF biomarker for Alzheimer's disease and dementia with Lewy bodies: effects of treatment with cholinesterase inhibitors European Journal of Neurology 2010 17 3 456 460
73. Alimonti A., Bocca B., Pino A., Ruggieri F., Forte G., Sancesario G., Elemental profile of cerebrospinal fluid in patients with Parkinson's disease Journal of Trace Elements in Medicine and Biology 2007 21 4 234 241
74. Asai H., Hirano M., Furiya Y., Udaka F., Morikawa M., Kanbayashi T., Shimizu T., Ueno S., Cerebrospinal fluid-orexin levels and sleep attacks in four patients with Parkinson's disease Clinical Neurology and Neurosurgery 2009 111 4 341 344
75. Bibl M., Esselmann H., Mollenhauer B., Weniger G., Welge V., Liess M., Lewczuk P., Otto M., Schulz J. B., Trenkwalder C., Kornhuber J., Wiltfang J., Blood-based neurochemical diagnosis of vascular dementia: a pilot study Journal of Neurochemistry 2007 103 2 467 474
76. Compta Y., Mart M. J., Ibarretxe-Bilbao N., Junqu C., Valldeoriola F., Muoz E., Ezquerra M., Ros J., Tolosa E., Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease Movement Disorders 2009 24 15 2203 2210
77. Lunardi G., Galati S., Tropepi D., Moschella V., Brusa L., Pierantozzi M., Stefani A., Rossi S., Fornai F., Fedele E., Stanzione P., Hainsworth A. H., Pisani A., Correlation between changes in CSF dopamine turnover and development of dyskinesia in Parkinson's disease Parkinsonism and Related Disorders 2009 15 5 383 389
78. Salehi Z., Mashayekhi F., Brain-derived neurotrophic factor concentrations in the cerebrospinal fluid of patients with Parkinson's disease Journal of Clinical Neuroscience 2009 16 1 90 93
79. Abdi F., Quinn J. F., Jankovic J., McIntosh M., Leverenz J. B., Peskind E., Nixon R., Nutt J., Chung K., Zabetian C., Sam A. II, Lin M., Hattan S., Pan C., Wang Y., Jin J., Zhu D., Li G. J., Liu Y., Waichunas D., Montine T. J., Zhang J., Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders Journal of Alzheimer's Disease 2006 9 3 293 348
80. Basso M., Giraudo S., Corpillo D., Bergamasco B., Lopiano L., Fasano M., Proteome analysis of human substantia nigra in Parkinson's disease Proteomics 2004 4 12 3943 3952
81. Davidsson P., Westman-Brinkmalm A., Nilsson C. L., Lindbjer M., Paulson L., Andreasen N., Sjgren M., Blennow K., Proteome analysis of cerebrospinal fluid proteins in Alzheimer patients NeuroReport 2002 13 5 611 615
82. Yin G. N., Lee H. W., Cho J.-Y., Suk K., Neuronal pentraxin receptor in cerebrospinal fluid as a potential biomarker for neurodegenerative diseases Brain Research 2009 1265 158 170
83. Tokuda T., Salem S. A., Allsop D., Mizuno T., Nakagawa M., Qureshi M. M., Locascio J. J., Schlossmacher M. G., El-Agnaf O. M. A., Decreased α-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease Biochemical and Biophysical Research Communications 2006 349 1 162 166
84. Irvine G. B., El-Agnaf O. M., Shankar G. M., Walsh D. M., Protein aggregation in the brain: the molecular basis for Alzheimer's and Parkinson's diseases Molecular Medicine 2008 14 7-8 451 464
85. Ono K., Noguchi-Shinohara M., Yoshita M., Naiki H., Yamada M., Cerebrospinal fluid of Alzheimer's disease and dementia with Lewy bodies patients enhances α-synuclein fibril formation in vitro Experimental Neurology 2007 203 2 579 583
86. Mukaetova-Ladinska E. B., Hurt J., Jakes R., Xuereb J., Honer W. G., Wischik C. M., α-synuclein inclusions in Alzheimer and Lewy body diseases Journal of Neuropathology and Experimental Neurology 2000 59 5 408 417
87. Harrington C. R., Mukaetova-Ladinska E. B., Hills R., Edwards P. C., De Garcini E. M., Novak M., Wischik C. M., Measurement of distinct immunochemical presentations of tau protein in Alzheimer disease Proceedings of the National Academy of Sciences of the United States of America 1991 88 13 5842 5846
88. Yao C., Williams A. J., Ottens A. K., Lu X.-C. M., Chen R., Wang K. K., Hayes R. L., Tortella F. C., Dave J. R., Detection of protein biomarkers using high-throughput immunoblotting following focal ischemic or penetrating ballistic-like brain injuries in rats Brain Injury 2008 22 10 723 732
89. The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging, Consensus report of the Working Group on: molecular and biochemical markers of Alzheimer's disease Neurobiology of Aging 1998 19 109 116
90. Buerger K., Zinkowski R., Teipel S. J., Tapiola T., Arai H., Blennow K., Andreasen N., Hofmann-Kiefer K., DeBernardis J., Kerkman D., McCulloch C., Kohnken R., Padberg F., Pirttil T., Schapiro M. B., Rapoport S. I., Mller H.-J., Davies P., Hampel H., Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 Archives of Neurology 2002 59 8 1267 1272
91. De Jong D., Jansen R. W. M. M., Pijnenburg Y. A. L., Van Geel W. J. A., Borm G. F., Kremer H. P. H., Verbeek M. M., CSF neurofilament proteins in the differential diagnosis of dementia Journal of Neurology, Neurosurgery and Psychiatry 2007 78 9 936 938
92. Arai H., Morikawa Y.-I., Higuchi M., Matsui T., Clark C. M., Miura M., Machida N., Lee V. M.-Y., Trojanowski J. Q., Sasaki H., Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology Biochemical and Biophysical Research Communications 1997 236 2 262 264
93. Engelborghs S., De Vreese K., Van de Casteele T., Vanderstichele H., Van Everbroeck B., Cras P., Martin J.-J., Vanmechelen E., De Deyn P. P., Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia Neurobiology of Aging 2008 29 8 1143 1159
94. Brazzelli M., Capitani E., Della Sala S., Spinnler H., Zuffi M., A neuropsychological instrument adding to the description of patients with suspected cortical dementia: the Milan overall dementia assessment Journal of Neurology Neurosurgery and Psychiatry 1994 57 12 1510 1517
95. Katsuse O., Iseki E., Marui W., Kosaka K., Developmental stages of cortical Lewy bodies and their relation to axonal transport blockage in brains of patients with dementia with Lewy bodies Journal of the Neurological Sciences 2003 211 1-2 29 35
96. Stokin G. B., Goldstein L. S. B., Axonal transport and Alzheimer's disease Annual Review of Biochemistry 2006 75 607 627
97. Oinas M., Polvikoski T., Sulkava R., Myllykangas L., Juva K., Notkola I.-L., Rastas S., Niinist L., Kalimo H., Paetau A., Neuropathologic findings of dementia with Lewy bodies (DLB) in a population-based Vantaa 85+ study Journal of Alzheimer's Disease 2009 18 3 677 689
98. Burn D. J., Perry E. K., OBrien J. T., Charney D. S., Nestler E. J., Dementia with Lewy bodies Neurobiology of Mental Illness 2009 3rd New York, NY, USA Oxford University Press 1010 1031
99. Tapiola T., Alafuzoff I., Herukka S.-K., Parkkinen L., Hartikainen P., Soininen H., Pirttil T., Cerebrospinal fluid -amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain Archives of Neurology 2009 66 3 382 389
100. Buerger K., Ewers M., Pirttil T., Zinkowski R., Alafuzoff I., Teipel S. J., DeBernardis J., Kerkman D., McCulloch C., Soininen H., Hampel H., CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease Brain 2006 129 11 3035 3041
101. Engelborghs S., Sleegers K., Cras P., Brouwers N., Serneels S., De Leenheir E., Martin J.-J., Vanmechelen E., Van Broeckhoven C., De Deyn P. P., No association of CSF biomarkers with APOE 4, plaque and tangle burden in definite Alzheimer's disease Brain 2007 130 9 2320 2326
102. Buerger K., Alafuzoff I., Ewers M., Pirttil T., Zinkowski R., Hampel H., No correlation between CSF tau protein phosphorylated at threonine 181 with neocortical neurofibrillary pathology in Alzheimer's disease Brain 2007 130 10 e82.1 e82.2
103. Mena R., Edwards P., Perez-Olvera O., Wischik C. M., Monitoring pathological assembly of tau and -amyloid proteins in Alzheimer's disease Acta Neuropathologica 1995 89 1 50 56
104. Huang X., Atwood C. S., Hartshorn M. A., Multhaup G., Goldstein L. E., Scarpa R. C., Cuajungco M. P., Gray D. N., Lim J., Moir R. D., Tanzi R. E., Bush A. I., The A peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction Biochemistry 1999 38 24 7609 7616 (Pubitemid 29289332)
105. Clinton L. K., Blurton-Jones M., Myczek K., Trojanowski J. Q., LaFerla F. M., Synergistic interactions between A, tau, and α-synuclein: acceleration of neuropathology and cognitive decline Journal of Neuroscience 2010 30 21 7281 7289
106. Hanson J. C., Lippa C. F., Lewy body dementia International Review of Neurobiology 2009 84 215 228
107. Maetzler W., Schmid B., Synofzik M., Schulte C., Riester K., Huber H., Brockmann K., Gasser T., Berg D., Melms A., The CST3 BB genotype and low cystatin C cerebrospinal fluid levels are associated with dementia in Lewy body disease Journal of Alzheimer's Disease 2010 19 3 937 942
108. Tizon B., Ribe E. M., Mi W., Troy C. M., Levy E., Cystatin C protects neuronal cells from amyloid- -induced toxicity Journal of Alzheimer's Disease 2010 19 3 885 894
109. Armstrong R. A., Cairns N. J., Size frequency distribution of the -amyloid (a ) deposits in dementia with Lewy bodies with associated Alzheimer's disease pathology Neurological Sciences 2009 30 6 471 477
110. Vanderstichele H., van Kerschaver E., Hesse C., Davidsson P., Buyse M.-A., Andreasen N., Minthon L., Wallin A., Blennow K., Vanmechelen E., Standardization of measurement of -amyloid(1-42) in cerebrospinal fluid and plasma Amyloid 2000 7 4 245 258
111. Schmidt R., Schmidt H., Curb J. D., Masaki K., White L. R., Launer L. J., Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia aging study Annals of Neurology 2002 52 2 168 174 (Pubitemid 34810596)
112. Gmez-Tortosa E., Gonzalo I., Fanjul S., Sainz M. J., Cantarero S., Cemilln C., Garca Ybenes J., Del Ser T., Cerebrospinal fluid markers in dementia with Lewy bodies compared with Alzheimer disease Archives of Neurology 2003 60 9 1218 1222 (Pubitemid 37099626)
113. Ernst A., Buerger K., Hartmann O., Dodel R., Noelker C., Sommer N., Schwarz M., Khrle J., Bergmann A., Hampel H., Midregional Proenkephalin A and N-terminal Protachykinin A are decreased in the cerebrospinal fluid of patients with dementia disorders and acute neuroinflammation Journal of Neuroimmunology 2010 221 1-2 62 67
114. Walker Z., Costa D. C., Walker R. W. H., Shaw K., Gacinovic S., Stevens T., Livingston G., Ince P., McKeith I. G., Katona C. L. E., Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand Journal of Neurology Neurosurgery and Psychiatry 2002 73 2 134 140
115. Francis P. T., Perry E. K., Cholinergic and other neurotransmitter mechanisms in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies Movement Disorders 2007 22 supplement 17 S351 S357
116. Shimada H., Hirano S., Shinotoh H., Aotsuka A., Sato K., Tanaka N., Ota T., Asahina M., Fukushi K., Kuwabara S., Hattori T., Suhara T., Irie T., Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET Neurology 2009 73 4 273 278
117. Piggott M. A., Ballard C. G., Rowan E., Holmes C., McKeith I. G., Jaros E., Perry R. H., Perry E. K., Selective loss of dopamine D2 receptors in temporal cortex in dementia with Lewy bodies, association with cognitive decline Synapse 2007 61 11 903 911
118. Klein J. C., Eggers C., Kalbe E., Weisenbach S., Hohmann C., Vollmar S., Baudrexel S., Diederich N. J., Heiss W. D., Hilker R., Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo Neurology 2010 74 11 885 892
119. Souza J. M., Giasson B. I., Chen Q., Lee V. M.-Y., Ischiropoulos H., Dityrosine cross-linking promotes formation of stable α-synuclein polymers: implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies Journal of Biological Chemistry 2000 275 24 18344 18349
120. Lippa C. F., Duda J. E., Grossman M., Hurtig H. I., Aarsland D., Boeve B. F., Brooks D. J., Dickson D. W., Dubois B., Emre M., Fahn S., Farmer J. M., Galasko D., Galvin J. E., Goetz C. G., Growdon J. H., Gwinn-Hardy K. A., Hardy J., Heutink P., Iwatsubo T., Kosaka K., Lee V. M.-Y., Leverenz J. B., Masliah E., McKeith I. G., Nussbaum R. L., Olanow C. W., Ravina B. M., Singleton A. B., Tanner C. M., Trojanowski J. Q., Wszolek Z. K., DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers Neurology 2007 68 11 812 819
121. Lovell M. A., Lynn B. C., Xiong S., Quinn J. F., Kaye J., Markesbery W. R., An aberrant protein complex in CSF as a biomarker of Alzheimer disease Neurology 2008 70 23 2212 2218
122. Fronczek R., Overeem S., Lee S. Y. Y., Hegeman I. M., Van Pelt J., Van Duinen S. G., Lammers G. J., Swaab D. F., Hypocretin (orexin) loss and sleep disturbances in Parkinson's Disease Brain 2008 131 1 e88
123. Yasui K., Inoue Y., Kanbayashi T., Nomura T., Kusumi M., Nakashima K., CSF orexin levels of Parkinson's disease, dementia with Lewy bodies, progressive supranuclear palsy and corticobasal degeneration Journal of the Neurological Sciences 2006 250 1-2 120 123
124. Oestreicher E., Sengstock G. J., Riederer P., Olanow C. W., Dunn A. J., Arendash G. W., Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study Brain Research 1994 660 1 8 18
125. Zhang J., Proteomics of human cerebrospinal fluidthe good, the bad, and the ugly ProteomicsClinical Applications 2007 1 8 805 819